With these findings in mind, we hereby confirmed the crucial role of G6PD level in breast cancer prognosis, which inspired us to probe the potential impact of G6PD in the combination therapy of pyrotinib plus chrysin against HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.